Pre-transplant Screening for Non-HLA Antibodies

Who should be Tested?

Mary Carmelle Philogene, Sheng Zhou, Bonnie E. Lonze, Serena M Bagnasco, Sami Alasfar, Robert A. Montgomery, Edward Kraus, Annette Jackson, Mary S. Leffell, Andrea A. Zachary

Research output: Contribution to journalArticle

Abstract

Retrospective studies of angiotensin II type 1 receptor antibodies (AT1R-Ab) and anti-endothelial cell antibodies (AECA) have linked these antibodies to allograft injury. Because rising healthcare costs dictate judicious use of laboratory testing, we sought to define characteristics of kidney transplant recipients who may benefit from screening for non-HLA antibodies. Kidney recipients transplanted between 2011 and 2016 at Johns Hopkins, were evaluated for AT1R-Ab and AECA. Pre-transplant antibody levels were compared to clinical and biopsy indications of graft dysfunction. Biopsies were graded using the Banff' 2009–2013 criteria. AT1R-Ab and AECA were detected using ELISA and endothelial cell crossmatches, respectively. AT1R-Ab levels were higher in patients who were positive for AECAs. Re-transplanted patients (p < 0.0001), males (p = 0.008) and those with FSGS (p = 0.04) and younger (p = 0.04) at time of transplantation were more likely to be positive for AT1R-Ab prior to transplantation. Recipients who were positive for AT1R-Ab prior to transplantation had increases in serum creatinine within 3 months post-transplantation (p < 0.0001) and developed abnormal biopsies earlier than did AT1R-Ab negative patients (126 days versus 368 days respectively; p = 0.02). Defining a clinical protocol to identify and preemptively treat patients at risk for acute rejection with detectable non-HLA antibodies is an important objective for the transplant community.

Original languageEnglish (US)
JournalHuman Immunology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Angiotensin Type 1 Receptor
Transplants
Antibodies
Transplantation
Biopsy
Kidney
Clinical Protocols
Health Care Costs
Allografts
Creatinine
Endothelial Cells
Retrospective Studies
Enzyme-Linked Immunosorbent Assay
anti-endothelial cell antibody
Wounds and Injuries
Serum

Keywords

  • Angiotensin II type 1 receptor antibody
  • Anti-endothelial cell antibodies
  • High immunologic risk patients
  • Kidney allograft dysfunction
  • Non-HLA antibodies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Pre-transplant Screening for Non-HLA Antibodies : Who should be Tested? / Philogene, Mary Carmelle; Zhou, Sheng; Lonze, Bonnie E.; Bagnasco, Serena M; Alasfar, Sami; Montgomery, Robert A.; Kraus, Edward; Jackson, Annette; Leffell, Mary S.; Zachary, Andrea A.

In: Human Immunology, 01.01.2018.

Research output: Contribution to journalArticle

Philogene, Mary Carmelle ; Zhou, Sheng ; Lonze, Bonnie E. ; Bagnasco, Serena M ; Alasfar, Sami ; Montgomery, Robert A. ; Kraus, Edward ; Jackson, Annette ; Leffell, Mary S. ; Zachary, Andrea A. / Pre-transplant Screening for Non-HLA Antibodies : Who should be Tested?. In: Human Immunology. 2018.
@article{12228af392d24bf881be080a26b6d216,
title = "Pre-transplant Screening for Non-HLA Antibodies: Who should be Tested?",
abstract = "Retrospective studies of angiotensin II type 1 receptor antibodies (AT1R-Ab) and anti-endothelial cell antibodies (AECA) have linked these antibodies to allograft injury. Because rising healthcare costs dictate judicious use of laboratory testing, we sought to define characteristics of kidney transplant recipients who may benefit from screening for non-HLA antibodies. Kidney recipients transplanted between 2011 and 2016 at Johns Hopkins, were evaluated for AT1R-Ab and AECA. Pre-transplant antibody levels were compared to clinical and biopsy indications of graft dysfunction. Biopsies were graded using the Banff' 2009–2013 criteria. AT1R-Ab and AECA were detected using ELISA and endothelial cell crossmatches, respectively. AT1R-Ab levels were higher in patients who were positive for AECAs. Re-transplanted patients (p < 0.0001), males (p = 0.008) and those with FSGS (p = 0.04) and younger (p = 0.04) at time of transplantation were more likely to be positive for AT1R-Ab prior to transplantation. Recipients who were positive for AT1R-Ab prior to transplantation had increases in serum creatinine within 3 months post-transplantation (p < 0.0001) and developed abnormal biopsies earlier than did AT1R-Ab negative patients (126 days versus 368 days respectively; p = 0.02). Defining a clinical protocol to identify and preemptively treat patients at risk for acute rejection with detectable non-HLA antibodies is an important objective for the transplant community.",
keywords = "Angiotensin II type 1 receptor antibody, Anti-endothelial cell antibodies, High immunologic risk patients, Kidney allograft dysfunction, Non-HLA antibodies",
author = "Philogene, {Mary Carmelle} and Sheng Zhou and Lonze, {Bonnie E.} and Bagnasco, {Serena M} and Sami Alasfar and Montgomery, {Robert A.} and Edward Kraus and Annette Jackson and Leffell, {Mary S.} and Zachary, {Andrea A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.humimm.2018.02.001",
language = "English (US)",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Pre-transplant Screening for Non-HLA Antibodies

T2 - Who should be Tested?

AU - Philogene, Mary Carmelle

AU - Zhou, Sheng

AU - Lonze, Bonnie E.

AU - Bagnasco, Serena M

AU - Alasfar, Sami

AU - Montgomery, Robert A.

AU - Kraus, Edward

AU - Jackson, Annette

AU - Leffell, Mary S.

AU - Zachary, Andrea A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Retrospective studies of angiotensin II type 1 receptor antibodies (AT1R-Ab) and anti-endothelial cell antibodies (AECA) have linked these antibodies to allograft injury. Because rising healthcare costs dictate judicious use of laboratory testing, we sought to define characteristics of kidney transplant recipients who may benefit from screening for non-HLA antibodies. Kidney recipients transplanted between 2011 and 2016 at Johns Hopkins, were evaluated for AT1R-Ab and AECA. Pre-transplant antibody levels were compared to clinical and biopsy indications of graft dysfunction. Biopsies were graded using the Banff' 2009–2013 criteria. AT1R-Ab and AECA were detected using ELISA and endothelial cell crossmatches, respectively. AT1R-Ab levels were higher in patients who were positive for AECAs. Re-transplanted patients (p < 0.0001), males (p = 0.008) and those with FSGS (p = 0.04) and younger (p = 0.04) at time of transplantation were more likely to be positive for AT1R-Ab prior to transplantation. Recipients who were positive for AT1R-Ab prior to transplantation had increases in serum creatinine within 3 months post-transplantation (p < 0.0001) and developed abnormal biopsies earlier than did AT1R-Ab negative patients (126 days versus 368 days respectively; p = 0.02). Defining a clinical protocol to identify and preemptively treat patients at risk for acute rejection with detectable non-HLA antibodies is an important objective for the transplant community.

AB - Retrospective studies of angiotensin II type 1 receptor antibodies (AT1R-Ab) and anti-endothelial cell antibodies (AECA) have linked these antibodies to allograft injury. Because rising healthcare costs dictate judicious use of laboratory testing, we sought to define characteristics of kidney transplant recipients who may benefit from screening for non-HLA antibodies. Kidney recipients transplanted between 2011 and 2016 at Johns Hopkins, were evaluated for AT1R-Ab and AECA. Pre-transplant antibody levels were compared to clinical and biopsy indications of graft dysfunction. Biopsies were graded using the Banff' 2009–2013 criteria. AT1R-Ab and AECA were detected using ELISA and endothelial cell crossmatches, respectively. AT1R-Ab levels were higher in patients who were positive for AECAs. Re-transplanted patients (p < 0.0001), males (p = 0.008) and those with FSGS (p = 0.04) and younger (p = 0.04) at time of transplantation were more likely to be positive for AT1R-Ab prior to transplantation. Recipients who were positive for AT1R-Ab prior to transplantation had increases in serum creatinine within 3 months post-transplantation (p < 0.0001) and developed abnormal biopsies earlier than did AT1R-Ab negative patients (126 days versus 368 days respectively; p = 0.02). Defining a clinical protocol to identify and preemptively treat patients at risk for acute rejection with detectable non-HLA antibodies is an important objective for the transplant community.

KW - Angiotensin II type 1 receptor antibody

KW - Anti-endothelial cell antibodies

KW - High immunologic risk patients

KW - Kidney allograft dysfunction

KW - Non-HLA antibodies

UR - http://www.scopus.com/inward/record.url?scp=85044527058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044527058&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2018.02.001

DO - 10.1016/j.humimm.2018.02.001

M3 - Article

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

ER -